Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Impact of Tocilizumab on Inflammatory Markers and Oxygen Status in Severe COVID-19 Patients: A Single Centre Retrospective Study

Author(s): Abhishek Sharma, Deepak Nathiya*, Supriya Suman, Hemant Bareth, Mahaveer Singh* and Eshan Sharma

Volume 22, Issue 5, 2022

Published on: 26 April, 2022

Article ID: e210222201328 Pages: 7

DOI: 10.2174/1871526522666220221143920

Price: $65

Abstract

Objective: This retrospective study aims to investigate the impact of tocilizumab on inflammatory markers in patients with severe COVID-19. The effect on oxygenation was also assessed.

Methods: This study is a single-centre, retrospective cohort study conducted at NIMS hospital. Data of the eligible patients with severe COVID-19 pneumonia who received injection tocilizumab (max 800 mg) were charted and analysed. Oxygenation and inflammatory markers were compared before and after (day 3 and day 7) tocilizumab injection. Effect of dysglycemia on the efficacy of tocilizumab was assessed. Outcomes were analysed in the form of discharge without oxygen, discharge with oxygen, and death. Data were analysed by SPSS v22.

Results: The mean age of the subjects was 57.8 ± 12.2 years, and 78.57% were male. Forty-four percent of the patient had type 2 diabetes. Tocilizumab treatment was associated with reduction in the oxygen requirement [median:10 L/min (IQR6- 14)] v/s 4 L/min (IQR 3-7, p-0.005]. Peripheral oxygen saturation also improved after tocilizumab [92 % (IQR 90-96)] v/s [95 % (IQR 94-96), p-0.01)], respectively. Serum CRP level decreased significantly when evaluated after three days (44±5 v/s 20 ±3 mg/dl, p=< 0.001). Out of the 42, 12 (29%) patients died due to severe COVID-19 or its complications. When compared with the patients who survived, patients who died had a higher level of D-dimer (1.2 ± 0.51 v/s 3.1 ±1.2 ng/dl, p-value- 0.04), and LDH: (845 ±55 v/s 1364 ±198 U/L, p - 0.01). At day seven of the tocilizumab injection, diabetic patients (n-13) had higher IL-6 serum level than nondiabetic patients (n-16) [(median- 311(IQR-1245.5) v/s (209 (IQR-546.2), p-value- 0.048].

Conclusion: In this retrospective pre-post analysis, tocilizumab injection was associated with reduced inflammation and improved oxygenation in severe COVID-19. Despite high IL-6 levels, diabetes had no impact on the efficacy of the tocilizumab.

Keywords: Oxygenation status, IL6, D-dimer, CRP, diabetes, tocilizumab, COVID-19 severe patients.

Graphical Abstract

[1]
Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020; 36(7): e3319.
[http://dx.doi.org/10.1002/dmrr.3319] [PMID: 32233013]
[2]
Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019; 4(20): 131774.
[http://dx.doi.org/10.1172/jci.insight.131774] [PMID: 31550243]
[3]
Marfella R, Paolisso P, Sardu C, et al. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab 2020; 46(5): 403-5.
[http://dx.doi.org/10.1016/j.diabet.2020.05.005] [PMID: 32447102]
[4]
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs. usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern Med 2021; 18(1): 32-40.
[PMID: 33080017]
[5]
Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. EClinicalMedicine 2022; 47: 101409.
[http://dx.doi.org/10.1101/2020.08.27.20183442]
[6]
Gokhale Y, Mehta R, Kulkarni U, et al. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: A retrospective cohort study with follow-up from Mumbai, India. BMC Infect Dis 2021; 21(1): 241.
[7]
Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J 2020; 56(4): 20003006.
[8]
Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med 2020; 383(23): 2255-73.
[http://dx.doi.org/10.1056/NEJMra2026131] [PMID: 33264547]
[9]
Hill JA, Menon MP, Dhanireddy S, et al. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol 2021; 93(4): 2270-80.
[http://dx.doi.org/10.1002/jmv.26674] [PMID: 33200828]
[10]
Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, et al. Tocilizumab for patients with severe COVID-19: A retrospective, multi-center study. Expert Rev Anti Infect Ther 2021; 19(1): 93-100.
[http://dx.doi.org/10.1080/14787210.2020.1800453]
[11]
Knorr JP, Colomy V, Mauriello CM, Ha S. Tocilizumab in patients with severe COVID-19: A single-center observational analysis. J Med Virol 2020; 92(11): 2813-20.
[http://dx.doi.org/10.1002/jmv.26191] [PMID: 32628003]
[12]
Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): An open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med 2021; 9(5): 511-21.
[http://dx.doi.org/10.1016/S2213-2600(21)00081-3] [PMID: 33676589]
[13]
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021; 384(1): 20-30.
[http://dx.doi.org/10.1056/NEJMoa2030340] [PMID: 33332779]
[14]
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med 2020; 383(24): 2333-44.
[http://dx.doi.org/10.1056/NEJMoa2028836] [PMID: 33085857]
[15]
McNeill JN, Lau ES, Paniagua SM, et al. The role of obesity in inflammatory markers in COVID-19 patients. Obes Res Clin Pract 2021; 15(1): 96-9.
[http://dx.doi.org/10.1016/j.orcp.2020.12.004] [PMID: 33390322]
[16]
Röhrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Frontiers in Immunology 2015; 6(JUL): 386.
[17]
Campisi G, Bizzoca ME, lo Muzio L. A new exciting hypothesis: direct correlation between periodontitis and clinical evolution of COVID-19 patients Qeios 2020 Preprint.
[http://dx.doi.org/10.32388/WK61AM.2]
[18]
Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol 2020; 8(10): 823-33.
[http://dx.doi.org/10.1016/S2213-8587(20)30271-0] [PMID: 32798471]
[19]
McGurnaghan SJ, Weir A, Bishop J, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: A cohort study of the total population of Scotland. Lancet Diabetes Endocrinol 2021; 9(2): 82-93.
[http://dx.doi.org/10.1016/S2213-8587(20)30405-8] [PMID: 33357491]
[20]
Zheng M, Wang X, Guo H, et al. The cytokine profiles and immune response are increased in COVID-19 patients with type 2 diabetes mellitus. J Diabetes Res 2021; 2021: 9526-701.
[21]
Administration D. IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects Guidance for Sponsors, Investigators, and Institutional Review Boards IRB Waiver or Alteration of Informed Consent for Clinica. US Dep Heal Hum Serv Food Drug Adm 2017. Available from: https://www.fda.gov/media/106587/download

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy